Cargando…

The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Vandendriessche, Benjamin, Rogge, Elke, Goossens, Vera, Vandenabeele, Peter, Stasch, Johannes-Peter, Brouckaert, Peter, Cauwels, Anje
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765536/ http://dx.doi.org/10.1186/2050-6511-14-S1-P75

Ejemplares similares

The Soluble Guanylate Cyclase Activator BAY 58-2667 Protects against Morbidity and Mortality in Endotoxic Shock by Recoupling Organ Systems
por: Vandendriessche, Benjamin, et al.
Publicado: (2013)

Pharmacological preconditioning with the guanylate cyclase activator cinaciguat (BAY 58-2667) protects against reperfusion injury after cardiopulmonary bypass
por: Radovits, Tamás, et al.
Publicado: (2009)

Relaxant effect of BAY 41-2272 and BAY 58-2667 in the gastrointestinal tract of apo-sGC mice
por: Cosyns, Sarah, et al.
Publicado: (2011)

Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
por: Frey, Reiner, et al.
Publicado: (2011)

The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy
por: Irvine, Jennifer C., et al.
Publicado: (2012)

Antihypertrophic actions of NO-independent soluble guanylyl cyclase (sGC) ligands BAY 41-2272 and BAY 58-2667 in vitro
por: Ritchie, Rebecca, et al.
Publicado: (2009)

Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls
por: Scheerans, Christian, et al.
Publicado: (2011)

Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice
por: Thoonen, Robrecht, et al.
Publicado: (2015)

Nitrite protects against morbidity and mortality associated with TNF- or LPS-induced shock in a soluble guanylate cyclase–dependent manner
por: Cauwels, Anje, et al.
Publicado: (2009)

BAY 58-2667, an NO-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts
por: Krieg, Thomas, et al.
Publicado: (2009)

Reactive oxygen species and small-conductance calcium-dependent potassium channels are key mediators of inflammation-induced hypotension and shock
por: Cauwels, Anje, et al.
Publicado: (2010)

Hypoxic NO-donor nitrite protects sGC-dependently against morbidity and mortality associated with sterile inflammatory shock in mice
por: Cauwels, A, et al.
Publicado: (2011)

Comparative Studies of the Dynamics Effects of BAY60-2770 and BAY58-2667 Binding with Human and Bacterial H-NOX Domains
por: Rehan Khalid, Rana, et al.
Publicado: (2018)

MAPK-activated protein kinase 2-deficiency causes hyperacute tumor necrosis factor-induced inflammatory shock
por: Vandendriessche, Benjamin, et al.
Publicado: (2014)

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
por: Mittendorf, Joachim, et al.
Publicado: (2009)

NO-insensitive sGCbeta1 H105F knockin mice: if NO has no place to go
por: Thoonen, Robrecht, et al.
Publicado: (2009)

Extracellular ATP drives systemic inflammation, tissue damage and mortality
por: Cauwels, A, et al.
Publicado: (2014)

Phenotypes of sGC mutant mice in basic conditions, disease and shock
por: Brouckaert, Peter, et al.
Publicado: (2009)

Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure
por: Mitrovic, Veselin, et al.
Publicado: (2009)

Fluorescence Dequenching Makes Haem-Free Soluble Guanylate Cyclase Detectable in Living Cells
por: Hoffmann, Linda S., et al.
Publicado: (2011)

Gender-Specific Modulation of the Response to Arterial Injury by Soluble Guanylate Cyclase α1
por: Vermeersch, Pieter, et al.
Publicado: (2009)

Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats
por: Hoffmann, Linda S., et al.
Publicado: (2015)

Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension
por: Hoffmann, Linda S, et al.
Publicado: (2013)

The uremic retention solute p-cresyl sulfate alters NO signal transduction by alteration of the soluble guanylate cyclase redox state
por: Meijers, Björn KI, et al.
Publicado: (2009)

Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis
por: Evgenov, Oleg V, et al.
Publicado: (2011)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
por: Frey, Reiner, et al.
Publicado: (2009)

Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats
por: Geschka, Sandra, et al.
Publicado: (2011)

Genetic mapping of a modifier locus affecting hypertension in soluble guanylate cyclase α(1) deficient mice
por: Buys, Emmanuel S, et al.
Publicado: (2011)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteosomal degradation
por: Meurer, Sabine, et al.
Publicado: (2009)

Activation of heme-free soluble guanylate cyclase with cinaciguat has beneficial cardiorenal actions when added to furosemide in experimental heart failure
por: Boerrigter, Guido, et al.
Publicado: (2011)

Soluble guanylate cyclase activator BAY 54–6544 improves vasomotor function and survival in an accelerated ageing mouse model
por: Ataei Ataabadi, Ehsan, et al.
Publicado: (2022)

Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease
por: Cortese-Krott, Miriam M., et al.
Publicado: (2017)

Structural studies of soluble guanylate cyclase
por: Macdonald, Jane, et al.
Publicado: (2009)

Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease
por: Bénardeau, Agnès, et al.
Publicado: (2021)

Cardiac soluble guanylate cyclase protects against the cardiac dysfunction induced by chronic doxorubicin treatment in mice
por: Vandenwijngaert, Sara, et al.
Publicado: (2015)

Nitric oxide synthase 2-derived NO in endotoxemia is not sufficient to cause hemodynamic effects
por: Brouckaert, P, et al.
Publicado: (2008)

Soluble Guanylate Cyclase Stimulators in Heart Failure
por: Kansakar, Sajog, et al.
Publicado: (2021)

Nucleotidyl cyclase activity of recombinant soluble guanylyl cyclase
por: Rauch, Kerstin, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_udfbjf4ila1jg87f3l2n0ahjqn